Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating regulatory nuggets about the SSi Mantra surgical robotic system inside a 300-page filing is tedious. SS Innovations’ disclosures span R&D spending for new cardiac instruments, global regulatory milestones, and surgeon adoption metrics—layers of detail that can slow decision-making.
Stock Titan solves that problem. Our AI reads every SS Innovations quarterly earnings report 10-Q filing, flags changes in production costs, and translates medical-device jargon into plain language. Wondering about SS Innovations insider trading Form 4 transactions? Receive real-time alerts the moment executives trade shares, complete with context you can understand in seconds. From the latest SS Innovations annual report 10-K simplified to a sudden SS Innovations 8-K material events explained, every document arrives on your screen as soon as it hits EDGAR—already summarized.
Use cases investors rely on daily:
- Compare R&D outlays across robotic platforms with our AI-driven 10-K analysis
- Track SS Innovations executive stock transactions Form 4 before product-launch announcements
- Review surgeon-training commitments buried in the proxy—SS Innovations proxy statement executive compensation details included
Whether you need SS Innovations SEC filings explained simply or deep SS Innovations earnings report filing analysis, our platform delivers comprehensive coverage—10-Ks, 10-Qs, 8-Ks, S-1s, and more—paired with clear, AI-powered insights so you can act with confidence.
SS Innovations International, Inc. disclosed that its Chairman and CEO, Dr. Sudhir Srivastava, took part in an interview with Nasdaq’s Live From MarketSite on November 13, 2025, which was published on December 16, 2025. The video can be viewed on Nasdaq’s Live From MarketSite website and via the company’s investor overview page. The company emphasizes that this interview is being furnished, not filed, under Regulation FD and is not incorporated by reference into other SEC reports, and it includes standard cautionary language about forward-looking statements and related risks.
SS Innovations International, Inc. (SSII)3,300 shares at a price of $0.00 per share. After this transaction, the insider beneficially owns 7,863,588 shares of SSII common stock in direct ownership. No derivative securities transactions were reported.
SS Innovations International (SSII) reported an insider transaction by Chairman and CEO Sudhir Srivastava. On 11/05/2025, he reported a code G gift of 30,000 shares of common stock at $0. Following the transaction, he beneficially owns 112,553,014 shares indirectly through Sushruta Pvt. Ltd.
Srivastava is listed as a Director and 10% Owner, and the shares are held of record by an entity he controls.
SS Innovations International, Inc. (SSII) furnished an updated November 2025 Company Presentation under Item 7.01 (Regulation FD Disclosure). The presentation is attached as Exhibit 99.1.
The materials are deemed “furnished,” not “filed,” which limits their applicability under Section 18 of the Exchange Act and they are not incorporated by reference into other filings. The notice includes customary forward‑looking statements language, highlighting that actual results may differ due to risks described in the company’s periodic reports.
SS Innovations International (SSII) reported a technology milestone. The company announced the successful completion of the first telesurgery performed using its SSi Mantra Tele Surgeon Console. The system is a compact, self-contained, chair-based version of the larger SSi Mantra command center, designed for portability, smaller spaces, and telesurgery from varied settings, including physician offices.
The announcement was made on November 6, 2025, and a detailed press release was furnished as Exhibit 99.1.
SS Innovations International (SSII)
The information in Items 2.02 and 7.01, and Exhibit 99.1, is deemed “furnished” rather than “filed,” and is not subject to Section 18 liabilities or incorporated by reference into other filings.
SS Innovations International (SSII) filed its quarterly report and reported strong top-line growth with continued losses. Q3 revenue was $12.83M, up from $4.39M a year ago, driven by system sales. Gross profit rose to $6.16M from $2.32M. The company posted a Q3 net loss of $3.72M and a year‑to‑date net loss of $9.66M, an improvement from $17.23M in the prior‑year period.
As of September 30, 2025, total cash, cash equivalents and restricted cash were $12.04M; current cash and cash equivalents were $5.68M. Working capital showed a surplus of $27.24M. Operating cash outflow was $17.02M year‑to‑date, partly offset by $24.79M of net financing inflows, including issuance of $28.0M of one‑year 7% convertible notes and subsequent conversions totaling 21.86M shares. Inventory increased to $20.04M from $10.21M to support demand.
The company disclosed “substantial doubt” about its ability to continue as a going concern, citing ongoing losses and reliance on related‑party funding even after its April 2025 Nasdaq uplisting. During Q3, it sold 28 surgical robotic systems (55 year‑to‑date). Revenue was concentrated in India, which represented 94% of Q3 sales.
SS Innovations International (SSII) announced management participation in two investor conferences. The company will join the UBS Global Healthcare Conference in Palm Beach Gardens, FL on November 11, 2025, and the Stifel 2025 Healthcare Conference in New York, NY on November 12, 2025. The Stifel event includes a group presentation at 4:40 p.m. Eastern Time.
A live webcast and replay of the Stifel presentation will be available on the company’s website at https://ssinnovations.com/investor-overview/. The disclosure is provided under Item 7.01 (Regulation FD) and is deemed “furnished,” not “filed.”
SS Innovations International (SSII) furnished an updated October 2025 Company Presentation under Item 7.01 (Regulation FD). The presentation is attached as Exhibit 99.1 and is intended for communications with shareholders and the investment community.
The information is deemed “furnished” rather than “filed,” meaning it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings. The report also includes standard forward‑looking statements cautionary language.
Amar Naveen Kumar is reported as an officer (CFO) and director of SS Innovations International, Inc. (SSII). The Form 3 shows no beneficial ownership of the issuer's common stock and no derivative holdings are disclosed. The filing provides the reporting person's address in Fort Lauderdale, FL and includes the required signature attestation.
FAQ
What is the current stock price of SS Innovations (SSII)?
What is the market cap of SS Innovations (SSII)?
